Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOmentum). A double-blind, randomised placebo-controlled phase 2/3 trial - Cree, B AC; Bennett, J L; Kim, H J (Lancet, 2019)
et al.